芪参汤治疗非酒精性脂肪性肝炎的临床疗效观察及对肠道菌群的影响

袁维; 王炳予; 杨磊; 张雅丽; 袁星星

doi:10.3969/j.issn.1671-038X.2021.06.02

芪参汤治疗非酒精性脂肪性肝炎的临床疗效观察及对肠道菌群的影响

- 1. 湖南中医药大学第一附属医院肝病科;
- 湖南中医药大学中医学国内一流建设学科(长沙, 410007);
- 2. 黑龙江省中医药科学院南岗分院消化科
基金项目:
国家自然科学基金青年基金(No:81904182)

湖南省自然科学基金(No:2020JJ5441)

黑龙江省中医药科研项目(No:ZHY18-029,ZHY19-061,ZHY19-062,ZHY2020-041)

详细信息

通讯作者: 袁星星,E-mail:jackieaqi@163.com

中图分类号: R575.1

收稿日期: 2020-12-07

Clinical effect of Qishen decoction on nonalcoholic steatohepatitis and its influence on gut microbiota

- 1. Department of Hepatology, the First Affiliated Hospital of Hunan University of Traditional Chinese Medicine;Discipline Construction Project of Traditional Chinese Medicine, Hunan University of Chinese Medicine, Changsha, 410007, China;
- 2. Department of Gastroenterology, Nangang Branch, Heilongjiang College of Traditional Chinese Medicine

More Information

Corresponding author: YUAN Xingxing, E-mail: jackieaqi@163.com

Received Date: 07 December 2020

摘要

摘要: 目的:观察芪参汤对非酒精性脂肪性肝炎(NASH)患者的临床疗效及对肠道菌群稳态的影响。方法:30例NASH患者随机分为治疗组(15例)和安慰剂组(15例),其中治疗组给予芪参汤治疗,安慰剂组给予芪参汤模拟剂治疗,疗程4周。分别观察2组患者治疗前后生化及纤维化指标的变化。另选取15例健康受试者作为对照,收集粪便样本通过16S rRNA检测各组肠道菌群的多样性和丰度。结果:与组内治疗前比较,芪参汤组治疗后AST、ALT、GGT、TC、TG、HA、LN、PⅢNP、CⅣ、LSM和CAP明显降低,HDL明显升高,差异有统计学意义(P<0.05),2组治疗后组间比较,芪参汤组均明显优于安慰剂组,差异均有统计学意义(P<0.05)。相关性分析结果显示,Phascolarctobacterium、Lactobacillus、Bifidobacterium、Akkermansia的丰度分别与LN、HA、PⅢNP、CIV、CAP、LSM和GGT水平呈现显著负相关,而Fusobacterium、Coprococcus、Bilophila和Prevotella的丰度分别与LN、HA、PⅢNP、CIV、CAP、LSM和GGT水平呈现显著正相关。此外,芪参汤组治疗后OTU、Chao1和Shannon指数与同组治疗前及健康受试者比较均明显增加,Simpon指数明显降低,差异均有统计学意义(P<0.05)。同时,与同组治疗前比较,芪参汤能够显著增加Clostridium、Roseburia、Eubacterium、Phascolarctobacterium、Lactobacillus、Parabacteroides、Pseudomonas、Bifidobacterium、Corynebacterium和Akkermansia菌属丰度,降低Faecalibacterium、Peptostreptococcus、Erysipelatoclostridium、Flavobacterium、Bilophila和Escherichia菌属丰度,差异均有统计学意义(P<0.05)。结论:芪参汤能通过增加NASH肠道菌群多样性和稳态,从而改善肝功能、血脂异常和纤维化水平,达到治疗NASH的作用。
- 芪参汤 /
- 非酒精性脂肪性肝炎 /
- 临床疗效 /
- 肠道菌群
Abstract: Objective: To observe the clinical efficacy of Qishen decoction on patients with nonalcoholic steatohepatitis(NASH) and its influence on gut microbiota.Methods: Thirty patients with NASH were randomLy divided into treatment group(n=15) and placebo group(n=15). The treatment group was treated with Qishen decoction, and the placebo group was treated with Qishen decoction simulant for 4 weeks. The changes of biochemical and fibrosis indexes were observed before and after treatment. Another 15 healthy subjects were selected as the control group. Fecal samples were collected and the diversity and abundance of gut microbiota in each group were detected by 16 S rRNA.Results: Compared with before treatment, AST, ALT, GGT, TC, TG, HA, LN, PⅢNP, CⅣ, LSM and CAP levels in Qishen decoction group were decreased, and the level of HDL was increased, differences were statistically significant(P<0.05), and the Qishen decoction group was significantly better than placebo group after treatment(P<0.05). The results of correlation analysis showed that the abundance of Phascolarctobacterium, Lactobacillus, Bifidobacterium, and Akkermansia were significantly negatively correlated with LN, HA, PⅢNP, CIV, CAP, LSM, and GGT levels(P<0.05), while the abundance of Fusobacterium, Coprococcus, Bilophila, and Prevotella were positively correlated with LN, HA, PⅢNP, CIV, CAP, LSM, and GGT respectively, and these differences were statistically significant(P<0.05). In addition, after treatment, OTU, Chao1 and Shannon index of Qishen decoction group were significantly increased, while Simpon index was significantly decreased when compared with those before treatment and healthy subjects(P<0.05). At the same time, Qishen decoction can significantly increase the abundance of Clostridium, Roseburia, Eubacterium, Phascolarctobacterium, Lactobacillus, Parabacteroides, Pseudomonas, Bifidobacterium, Corynebacterium, and Akkermansia, and reduce the abundance of Faecalibacterium, Peptostreptococcus, Erysipelatoclostrium, Flavobacterium, Bilophila, and Escherichia, and these differences were statistically significant(P<0.05).Conclusion: Qishen decoction can improve liver function, dyslipidemia and fibrosis by increasing the diversity and restoring the homeostasis of NASH gut microbiota.
- Qishen decoction /
- nonalcoholic steatohepatitis /
- clinical efficacy /
- gut microbiota

HTML全文

参考文献(23)

[1]	舒筠然,李俊琪,刘琼.非酒精性脂肪性肝病的流行病学和危险因素分析[J].临床肝胆病杂志,2019,35(9):2085-2090.
[2]	Sheka AC,Adeyi O,Thompson J,et al.Nonalcoholic Steatohepatitis:A Review[J].JAMA,2020,323(12):1175-1183.
[3]	Xu G,Ye J,Liu XJ,et al.Activation of pluripotent genes in hepatic progenitor cells in the transition of nonalcoholic steatohepatitis to pre-malignant lesions[J].Lab Invest,2017,97(10):1201-1217.
[4]	沈波,陆伦根.巨噬细胞髓细胞-上皮-生殖酪氨酸激酶促进NASH纤维化的机制及治疗策略[J].肝脏,2020,25(10):1021-1023.
[5]	李硕熙,袁星星,杨磊,等.基于网络药理学方法分析芪参汤治疗非酒精性脂肪性肝病的作用机制及实验验证[J].海南医学院学报,2020,26(14):1074-1082.
[6]	李硕熙,王炳予,杨磊,等.芪参汤通过PI3K/Akt/mTOR信号通路抗肝纤维化的机制研究[J].海南医学院学报,2020,26(12):905-909,914.
[7]	王炳予,张雅丽,杨磊,等.基于16S rRNA技术探讨芪参汤治疗非酒精性脂肪性肝纤维化的作用机制[J].海南医学院学报,2020,26(1):18-24,29.
[8]	中华医学会肝病学分会脂肪肝和酒精性肝病学组,中国医师协会脂肪性肝病专家委员会.非酒精性脂肪性肝病防治指南(2018更新版)[J].中华肝脏病杂志,2018,26(3):195-203.
[9]	李军祥,陈誩,王允亮.非酒精性脂肪性肝病中西医结合诊疗共识意见(2017年)[J].中国中西医结合消化杂志,2017,25(11):805-811.
[10]	中华医学会肝病学分会脂肪肝和酒精性肝病学组,中国医师协会脂肪性肝病专家委员会.非酒精性脂肪性肝病防治指南(2018更新版)[J].传染病信息,2018,31(5):393-402,420.
[11]	程贤文,张博,万文雅,等.脂肪性肝病中西医研究进展[J].中国中西医结合消化杂志,2019,27(4):318-322.
[12]	刘勤,牛春燕.由“二次打击”到“多重打击”:发病机制的演变带给非酒精性脂肪性肝病的治疗启示[J].世界华人消化杂志,2019,27(19):1171-1178.
[13]	周雨,张智伟,王京奇.从“二次打击”学说探讨中药防治非酒精性脂肪肝的研究进展[J].中医药导报,2017,23(18):109-111.
[14]	吴健.非酒精性脂肪性肝炎所致肝纤维化的机制及干预[J].中华肝脏病杂志,2019,27(6):415-419.
[15]	高明月,杨雅坤,殷雅楠,等.肠道菌群介导的非酒精性脂肪性肝病发病机制研究进展[J].解放军医学杂志,2020,45(9):990-995.
[16]	付懿铭,纪冬,邵清,等.肝脏硬度值及血清生化指标与非酒精性脂肪性肝炎的相关性分析[J].临床肝胆病杂志,2020,36(11):2473-2477.
[17]	陆伦根,尤红,谢渭芬,等.肝纤维化诊断及治疗共识(2019年)[J].临床肝胆病杂志,2019,35(10):2163-2172.
[18]	歧红阳,王志民,肖占宇,等.GPRI、LSM、GPC3、AFP联合检测在肝纤维化及肝癌中的应用价值[J].实用医院临床杂志,2019,16(4):268-270.
[19]	叶毅,郑亮,郑恩典,等.非酒精性脂肪性肝病的肠道菌群变化及粪菌移植治疗作用研究[J].中国中西医结合消化杂志,2019,27(10):758-763.
[20]	王蓉,谢伶俐,宋明宇.肠道微生物对慢性肝病影响的研究进展[J].中国中西医结合消化杂志,2019,27(11):879-882.
[21]	Li J,Lin S,Vanhoutte PM,et al.Akkermansia Muciniphila Protects Against Atherosclerosis by Preventing Metabolic Endotoxemia-Induced Inflammation in Apoe-/-Mice[J].Circulation,2016,133(24):2434-2446.
[22]	Greer RL,Dong X,Moraes AC,et al.Akkermansia muciniphila mediates negative effects of IFNγ on glucose metabolism[J].Nat Commun,2016,7:13329.
[23]	Depommier C,Everard A,Druart C,et al.Supplementation with Akkermansia muciniphila in overweight and obese human volunteers:a proof-of-concept exploratory study[J].Nat Med,2019,25(7):1096-1103.